The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Prediction of response to pelareorep plus pembrolizumab in pancreatic ductal adenocarcinoma (PDAC).
 
Christos Fountzilas
Consulting or Advisory Role - AstraZeneca (Inst)
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); BeiGene (Inst); Lilly (Inst); Merck (Inst)
 
Grey A Wilkinson
Employment - Oncolytics
Stock and Other Ownership Interests - Oncolytics
Patents, Royalties, Other Intellectual Property - Oncolytics
 
Kevin H. Eng
No Relationships to Disclose
 
Paul Fields
Employment - Adaptive Biotechnologies
Stock and Other Ownership Interests - Adaptive Biotechnologies
 
Sukeshi Patel Arora
Consulting or Advisory Role - Exelixis/Ipsen
Speakers' Bureau - Bayer; Exelixis
 
Pawel Kalinski
Consulting or Advisory Role - Immunicum; Kyn Therapeutics
Research Funding - Arrys Therapeutics
Travel, Accommodations, Expenses - Immunicum; Kyn Therapeutics
 
Patrick Raber
Employment - Adaptive Biotechnologies
Stock and Other Ownership Interests - Adaptive Biotechnologies
 
Gerard Nuovo
No Relationships to Disclose
 
Matthew C. Coffey
Employment - Oncolytics
Leadership - Oncolytics
Stock and Other Ownership Interests - Oncolytics
Patents, Royalties, Other Intellectual Property - Oncolytics
Travel, Accommodations, Expenses - Oncolytics
 
Devalingam Mahalingam
Honoraria - Amgen; Bayer; Bristol-Myers Squibb; EMD Serono; Genentech
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; EMD Serono
Speakers' Bureau - Amgen; Bayer; Bristol-Myers Squibb; Eisai; Genentech
Research Funding - Merck; Oncolytics
Expert Testimony - Blake Jones Law Firm